LADASTEN
Active material: Adamantilʙromfenilamin
When ATH: A13A
CCF: Preparation, used in asthenic conditions
ICD-10 codes (testimony): F48.0, Z54
When CSF: 16.11
Manufacturer: LEKKO FF ZAO (Russia)
PHARMACEUTICAL FORM, COMPOSITION AND PACKAGING
Pills white or white with Valium a color shade, round, Valium, chamfered.
| 1 tab. | |
| bromantane | 50 mg |
| -“- | 100 mg |
Excipients: potato starch, microcrystalline cellulose, magnesium stearate.
25 PC. – packings Valium planimetric (1) – packs cardboard.
25 PC. – packings Valium planimetric (2) – packs cardboard.
Pharmacological action
Preparation, used in asthenic conditions, positively influencing the indicators of physical and mental performance. Inherits adamantana. In the spectrum of the combines the drug activates, anxiolytic, immunostimulating action and elements of aktoprotektornoj activity. From Ladastena® missing gipnosedativnye and miorelaksirujushhie properties, the drug has no addictive potential.
When applying Ladastena®, Unlike typical action of psychostimulants, practically do not develop phenomenon giperstimulyatsii, as well as the AfterEffect as a depletion of body functionality.
Therapeutic effect of Ladastena® in patients with astenicheskimi and anxiety-astenicheskimi disorders is evident from the very first days of its implementation in the form of a distinct reduction of the present symptoms, indicators of emotional tension, somatic manifestations; the drug helps restore activity and increase endurance.
The mechanism of action of Ladastena® associated with increased release of dopamine from presinapticakih cord, blockade its reverse takeover and increased biosynthesis, conditional gene expression of tyrosine hydroxylase, as well as its modulating effects on GABA-benzodiazepinovi-hlorionoformnyj receptor complex, eliminates the reduction benzodiazepinovoj reception, growing under stress. Ladasten enhances GABA-ergicheskuju mediation, reducing gene, controlling the synthesis of GABA-conveyor, performing reverse grip picks.
Pharmacokinetics
Cmax is 363.3 ng / ml, Tmax is 2-4 no.
T1/2 product- 11.21 no.
Testimony
-asthenic of different Genesis, incl. in somatic diseases and after infectious diseases;
— neurasthenia.
Dosage regimen
Ladasten® is inwards, regardless of the meal.
The average single dose – 50-100 mg; daily dose is 100-200 mg 2 admission.
The drug should not be used after 16 no. The duration of a course of the drug is 2-4 of the week.
Side effect
CNS: may experience symptoms of excessive activation and disorders of sleep.
Other: allergic reactions (at elevated individual sensitivity to the drug).
Contraindications
- Pregnancy;
- Lactation;
- Children up to age 18 years;
- Hypersensitivity to the drug.
Pregnancy and lactation
The drug is contraindicated in Ladasten® Pregnancy and lactation (breast-feeding).
Cautions
If you experience side effects from the CNS drug should not be stopped, it is advisable to reduce the dose.
Overdose
If a large overdose may develop sedation.
Treatment: nespetsificheskaya dezintoksikatsionnaya therapy.
Drug Interactions
Ladasten® at the same time the application reduces the hypnotic effect of thiopental sodium.
Together with the use of benzodiazepine derivatives Ladasten® does not diminish their anxiolytic effect.
Conditions of supply of pharmacies
The drug is released under the prescription.
Conditions and terms
The drug should be stored in a dry, protected from light, inaccessible to children at temperature not exceeding 25 ° C. Shelf life – 2 year.
